You are here
Gout is the most common inflammatory arthritis affecting adults and, probably, one of the most underestimated.
Besides damaging joints and causing significant pain and disability, there are pathogenic mechanisms by which uric acid participates in the development of numerous comorbidities - including cardiovascular disease.
Prevention and early treatment of acute gout not only decreases the disability and economic burden associated with it, but may also lessen the impact of CV and other comorbidities. Hence, finding new ways to quickly and effectively resolve acute flares of gout could be priceless.
Joosten et al has generated a new protein, recombinant human alpha-1-anti-trypsin (AAT)-IgG1 Fc fusion protein (AAT-Fc), to evaluate its antiinflammatory potential in and IL-1 induced animal model of gouty arthritis. A single low dose of AAT-Fc was shown to be highly effective in reducing joint inflammation in an animal model of acute gouty arthritis. Considering the long-term safety of plasma-derived AAT use in humans, subcutaneous AAT-Fc may emerge as a promising therapy for gout attacks.